Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,665 across all filing types
Latest filing 2016-03-03 Interim / Quarterly Rep…
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
HSV-2 Phase II Initial Results 3 pages 381.6KB
Interim / Quarterly Report Classification · 90% confidence The document is an ASX announcement from Admedus Limited dated 4 March 2016. It reports interim clinical trial data from a Phase II HSV-2 vaccine study, including safety and efficacy observations. The content focuses on clinical trial progress and preliminary results rather than full financial statements or comprehensive periodic reporting. The document is about an interim update on clinical trial data, not a full interim financial report or earnings release. It is not a regulatory filing, certification, or announcement of a report publication. Given the nature of the content—interim clinical trial data and study progress—the best fitting category is 'Interim / Quarterly Report (IR)' as it provides substantive data for a period shorter than a full fiscal year, specifically interim clinical trial results. Confidence is high because the document contains detailed interim data and analysis, not just a brief announcement or summary. Q3 2016
2016-03-03 English
Half Yearly Report 29 pages 1.1MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Half Yearly Report (Appendix 4D) for the six months ended 31 Dec 2015' and contains detailed financial performance data, directors' report, financial statements, and audit report. It includes comprehensive financial results for the half-year period, management commentary, and operational highlights. The presence of an Appendix 4D and half-year financial report indicates this is a formal interim financial report. The document is about 15,000 characters long, which is consistent with a full interim report rather than a brief announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2016
2016-02-25 English
HSV-2 Study timelines update 3 pages 431.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Admedus Ltd providing an update on the timelines for interim data release from a Phase II HSV-2 vaccine study. It discusses study progress, expected data release timing, and clinical trial details. There are no financial statements, detailed financial analysis, or regulatory filings such as annual or quarterly reports. The document is a corporate announcement about clinical study progress and timing of data release, not a financial report or regulatory filing. It is not a report publication announcement since it does not mention a report being attached or published, but rather an update on study timelines. Therefore, the document fits best under the category of Regulatory Filings (RNS) as a general corporate announcement that does not fit other specific categories.
2016-02-14 English
Admedus appoints new Chairman 2 pages 424.8KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement from Admedus Limited dated 9 February 2016. It announces the appointment of a new Chairman and the resignation of two directors. The content focuses on changes in the company's board of directors, including biographical information about the new Chairman and acknowledgments of the outgoing directors. There is no financial data, no mention of a report being attached or published, and no other regulatory or financial reporting content. This fits the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2016-02-08 English
Final Director's Interest Notices 4 pages 223.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the securities holdings and interests of directors who have ceased to be directors, including the number and class of securities held and interests in contracts. This type of document is a formal notification of personal share transactions or holdings by company directors. It is not a financial report, earnings release, or management report. It fits the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length and content confirm it is not a brief announcement or a report publication notice but a substantive disclosure of director interests.
2016-02-08 English
Admedus Director steps down 2 pages 422.2KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement titled 'ADMEDUS DIRECTOR STEPS DOWN' and details the resignation of a board member, Mr. Peter Turvey, from the company's board of directors. It includes information about his role and tenure but does not contain financial data, report attachments, or references to financial results. The content clearly relates to a change in the company's board of directors. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and focused solely on this announcement, confirming it is not a full report or other filing type.
2016-02-07 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.